|
| Press Releases |
|
 |
|
| Thursday, July 25, 2024 |
|
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
| Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
| Tuesday, July 23, 2024 |
|
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
| The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
| Tuesday, July 16, 2024 |
|
|
エーザイ、ホスラブコナゾールのアジア・オセアニアにおけるライセンス契約を佐藤製薬と締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗真菌剤ホスラブコナゾールについて、真菌性疾患に対するアジア・オセアニアにおける開発および商業化に関するライセンス契約を佐藤製薬株式会社（本社：東京都、以下 佐藤製薬）と締結したことをお知らせします。 more info >> |
|
| Friday, July 12, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「レケンビ」（レカネマブ）がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ®」（一般名：レカネマブ）について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「LEQEMBI」（レカネマブ）が香港においてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性 アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ(R)」（香港製品名：「樂意保(R)」、一般名：レカネマブ）について、香港衛生署（Department of Health）より新薬承認を取得したことをお知らせします。 more info >> |
|
| Tuesday, July 2, 2024 |
|
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
| Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
| Friday, June 28, 2024 |
|
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
維昇藥業（2561.HK）維臻高(R)獲批：重長效生長激素王者登場 重構百億市場的商業天花板
Feb 25, 2026 14:58 HKT/SGT
|
|
|
Hong Kong Tech Delegation Heading for Market Expansion at Mobile World Congress 2026
Feb 25, 2026 14:54 HKT/SGT
|
|
|
CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential
Feb 25, 2026 12:46 HKT/SGT
|
|
|
Shoucheng Holdings (00697.HK) Sees Long-Term International Capital Rotation as Robotics Portfolio Enters Harvest Phase
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎來國際長線接盤 機器人產業生態進入價值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎来国际长线接盘 机器人产业生态进入价值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
ベイシアのスーパーマーケット内の冷蔵・冷凍庫の温度点検・記録業務を富士通のIoT可視化ソリューションにより自動化
Feb 25, 2026 12:00: JST
|
|
|
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 12:00 JST
|
|
|
國泰君安國際獲批使用SIMM 衍生品風險管理接軌國際標準
Feb 25, 2026 10:34 HKT/SGT
|
|
|
国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准
Feb 25, 2026 10:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 22:30: JST
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 21:30 HKT/SGT
|
|
|
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST
|
|
|
康哲藥業（867.HK/8A8.SG）：創新藥磷酸蘆可替尼乳膏增加特應性皮炎（AD）適應症中國上市許可申請獲受理並獲納入優先審評
Feb 24, 2026 20:31 HKT/SGT
|
|
|
康哲药业（867.HK/8A8.SG）：创新药磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症中国上市许可申请获受理并获纳入优先审评
Feb 24, 2026 20:19 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
